Program
Indication
Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
GO-4
Stage IV pancreatic cancer
Other solid metastatic cancers
Phase 1 expansion estimated completion, Q1 2027
Phase 2 initiation based on positive interim Phase 2 results in pancreatic cancer study
GO-2301
Proliferative retinopathy or wet AMD
IND enabling studies to begin Q3 2026
Next Generation
Metastatic and non-metastatic proliferative diseases
IND enabling studies to begin on one additional drug candidate in 2027
GO-4
Stage IV pancreatic cancer
Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
Phase 1 estimated completion, Q2 2027
GO-4
Other solid metastatic cancers
Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
Phase 2 initiation based on positive interim Phase 2 results in pancreatic cancer study
GO-2301
Proliferative retinopathy or wet AMD
Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
IND enabling studies to begin Q3 2026
Next Generation
Metastatic and non-metastatic proliferative diseases
Preclinical
IND-enabling
Phase 1
Phase 2 (Pivotal)
Submission
Next Milestone
IND enabling studies to begin on one additional drug candidate in 2027
We developed a pipeline of drug candidates for Stave IV solid cancers, as well as for myeloma, leukemia, and lymphoma.
We are developing a combination of melphalan, BCNU, vitamin B12b, and vitamin C for the treatment of Stage IV cancers in patients with an inherited BRCA1, BRCA2, or PALB2 mutation. Cancers currently under consideration are pancreatic and breast cancer.
Stay tuned.
